CSF tau protein: a new prognostic marker for Guillain-Barré syndrome.
We measured the CSF tau protein levels in 26 patients with Guillain-Barré syndrome. The levels of the poor outcome group (Hughes grade at 6 months was between II and VI, n = 6) were higher than those of the good outcome group (0 or I, n = 20) (p < 0.0005). The higher levels of CSF tau may reflect axonal degeneration and could predict a poor clinical outcome in Guillain-Barré syndrome.
Jin
K
K
Department of Neurology, Kohnan Hospital, Japan.
Takeda
A
A
Shiga
Y
Y
Sato
S
S
Ohnuma
A
A
Nomura
H
H
Arai
H
H
Kusunoki
S
S
Ikeda
M
M
Itoyama
Y
Y
D000328:Adult; D000368:Aged; D000906:Antibodies / Q000097:blood; D001369:Axons; D015415:Biomarkers / Q000134:cerebrospinal fluid; D004568:Electrodiagnosis; D005260:Female; D006017:Glycolipids / Q000276:immunology; D020275:Guillain-Barre Syndrome / Q000134:cerebrospinal fluid* / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009410:Nerve Degeneration / Q000209:etiology / Q000503:physiopathology; D017063:Outcome Assessment, Health Care; D011379:Prognosis; D012121:Respiration, Artificial; D016875:tau Proteins / Q000134:cerebrospinal fluid*
D000906:Antibodies; D015415:Biomarkers; D006017:Glycolipids; D016875:tau Proteins